The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market size is expected to see strong growth in the next few years. It will grow to $7.67 billion in 2028 at a compound annual growth rate (CAGR) of 7.7%. The growth in the forecast period can be attributed to telemedicine and remote monitoring, data analytics and ai, patient education and support, regulatory changes and reimbursement policies. Major trends in the forecast period include personalized treatment approaches, development of novel therapies, minimally invasive diagnostics, collaborative care models.
Order your report now for swift delivery @
https://www.thebusinessresearchcompany.com/report/exocrine-pancreatic-insufficiency-epi-therapeutics-and-diagnostics-global-market-report
Scope Of Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market
The Business Research Company’s reports encompass a wide range of information, including:
1. Market Size (Historic and Forecast): Analysis of the market’s historical performance and projections for future growth.
2. Drivers: Examination of the key factors propelling market growth.
3. Trends: Identification of emerging trends and patterns shaping the market landscape.
4. Key Segments: Breakdown of the market into its primary segments and their respective performance.
5. Focus Regions and Geographies: Insight into the most critical regions and geographical areas influencing the market.
6. Macro Economic Factors: Assessment of broader economic elements impacting the market.
Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Overview
Market Drivers –
The increasing number of people with diabetes is expected to propel the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market going forward. Diabetes refers to a chronic metabolic disorder characterized by high blood sugar levels (hyperglycemia) over a prolonged period. This condition results from the body’s inability to produce enough insulin or effectively use the insulin it produces. EPI therapy, which involves pancreatic enzyme replacement therapy (PERT), can help improve nutrient absorption in people with diabetes and EPI. It can also help improve glycemic control in people with diabetes. For instance, in November 2021, according to the International Diabetes Federation, a Belgium-based umbrella organization of over 230 national diabetes associations, approximately 537 million adults (20–79 years old) were living with diabetes in 2021, whereas the total number of people living with diabetes is projected to rise to 643 million by 2030 and 783 million by 2045. Therefore, the increasing number of people with diabetes is driving the growth of the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market.
Market Trends –
Major companies operating in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market are focused on innovating new studies and solutions, such as PACT-CP to sustain their position in the market. For instance, in June 2021, Aimmune Therapeutic, a US-based biopharmaceutical company, launched PACT-CP, a patient-centric chronic pancreatitis registry study, to better understand the unmet needs and therapeutic burden on patients with EPI due to chronic pancreatitis (CP). It is the first real-world registry study for patients with chronic pancreatitis. The study, which will follow about 400 patients at 20 gastroenterology facilities across the United States, was created with the help of patients and expert consultants. The PACT-CP Registry study is a prospective, non-interventional research study for patients receiving gastroenterology treatment diagnosed with EPI due to chronic pancreatitis.
The exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market covered in this report is segmented –
1) By Therapies: Nutritional Management; Pancreatic Enzyme Replacement Therapy (PERT); Lifestyle Modifications Approach
2) By Diagnostics: Blood Tests; Magnetic Resonance Imaging (MRI); Endoscopic Ultra-Sonography (EUS); Computerized Tomography (CT) Scanning
3) By Drug Type: Generic; Branded
4) By Distribution Channel: Direct Tender; Retail Pharmacy ; Third-Party Distributor; Other Distribution Channels
5) By End User: Hospitals; Specialty Clinics; Homecare; Diagnostic Center; Research And Academic Institutes; Other End Users
Get an inside scoop of the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market, Request now for Sample Report @
https://www.thebusinessresearchcompany.com/sample.aspx?id=12992&type=smp
Regional Insights –
North America was the largest region in the exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market in 2023. The regions covered in exocrine pancreatic insufficiency (EPI) therapeutics and diagnostics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
Key Companies –
Major players in the exocrine pancreatic insufficiency (epi) therapeutics and diagnostics market are Pfizer Inc., Merck & Co. Inc., Janssen Pharmaceuticals Inc., AbbVie Inc., Novartis AG, Sanofi S.A., AstraZeneca PLC, Abott Laboratories, Medtronic PLC, Solvay S.A., Laboratory Corporation of America Holdings (Labcorp), Organon group of companies Metagenics LLC, Allergan PLC, Chiesi Farmaceutici S.p.A., Codexis Inc., Nordmark Arzneimittel GmbH & Co. KG, ChiRhoClin Inc., Digestive Care Inc., Alcresta Therapeutics Inc., Vivus Inc., Cilian AG, Bioserv Diagnostics Gmbh, Anthera Pharmaceuticals Inc., Aptalis Pharma Inc., First Wave BioPharma Inc., EagleBiosciences Inc., ScheBo Biotech AG.
Table of Contents
1. Executive Summary
2. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Report Structure
3. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Trends And Strategies
4. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market – Macro Economic Scenario
5. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Size And Growth
…..
27. Exocrine Pancreatic Insufficiency (EPI) Therapeutics And Diagnostics Market Competitor Landscape And Company Profiles
28. Key Mergers And Acquisitions
29. Future Outlook and Potential Analysis
30. Appendix
Read Related Topics:
https://goodprnews.com/small-cell-lung-cancer-therapeutics-market-size/
https://goodprnews.com/congenital-diaphragmatic-hernia-drugs-market-size/
https://goodprnews.com/reversible-airway-diseases-treatment-market-size/
https://topprnews.com/small-cell-lung-cancer-therapeutics-market-share/
https://topprnews.com/congenital-diaphragmatic-hernia-drugs-market-share/
https://topprnews.com/reversible-airway-diseases-treatment-market-share/
Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293
Email: [email protected]
Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
